3045SP |
Modafinil / Armodafinil, Serum/Plasma |
3063SP |
Mycophenolic Acid and Metabolite, Serum/Plasma |
3063U |
Mycophenolic Acid and Metabolite, Urine |
3082SP |
Molindone, Serum/Plasma |
3082U |
Molindone, Urine |
3098U |
Mono-n-butyl phthalate (MNBP), Urine |
3099U |
Phthalates Panel, Urine |
3111SP |
Naloxone - Free (Unconjugated), Serum/Plasma |
3111U |
Naloxone - Total (Conjugated/Unconjugated), Urine |
3113U |
Naloxone - Total (Conjugated/Unconjugated) Screen, Urine |
3116SP |
Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma |
3116U |
Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine |
3118SP |
Nateglinide, Serum/Plasma |
3145SP |
Nefazodone, Serum/Plasma |
3145U |
Nefazodone, Urine |
3150SP |
Nicotine and Metabolite, Serum/Plasma |
3150U |
Nicotine and Metabolite with Anabasine, Urine |
3157U |
Cotinine and Anabasine from Secondary Exposure, Urine |
3225SP |
Nuedexta®, Serum/Plasma |
3226SP |
Olanzapine and Metabolite, Serum/Plasma |
3265SP |
Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Serum/Plasma |
3325SP |
Paraquat, Serum/Plasma |
3427SP |
Perfluoroalkyl Substances (PFAS), Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3428SP |
PFASure TM, Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3429SP |
PFASure TM Expanded, Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3433SP |
Perampanel, Serum/Plasma |
3440SP |
Perphenazine, Serum/Plasma |
3510U |
Phenacetin and Metabolite, Urine |
3690SP |
Phentermine, Serum/Plasma |
3690U |
Phentermine, Urine |
3707SP |
Phenylethylmalonamide, Serum/Plasma |
3743SP |
Phenytoin, Serum/Plasma |
3776SP |
Pimozide, Serum/Plasma |
3779SP |
Pioglitazone, Serum/Plasma |
3901SP |
Primidone, Serum/Plasma |
3970SP |
Promethazine, Serum/Plasma |
3970U |
Promethazine, Urine |